Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7657 USD | -0.30% | -0.91% | -19.18% |
Financials (USD)
Sales 2024 * | 2M | Sales 2025 * | 3.33M | Capitalization | 55.74M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -106M | EV / Sales 2024 * | 27.9 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 16.7 x |
P/E ratio 2024 * |
-0.61
x | P/E ratio 2025 * |
-0.63
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.16% |
Latest transcript on Kezar Life Sciences, Inc.
1 day | -0.30% | ||
1 week | -0.91% | ||
Current month | -7.13% | ||
1 month | -6.23% | ||
3 months | -8.85% | ||
6 months | -10.95% | ||
Current year | -19.18% |
Managers | Title | Age | Since |
---|---|---|---|
Christopher Kirk
FOU | Founder | 52 | 15-02-18 |
John Fowler
FOU | Founder | 52 | 15-02-18 |
Marc Belsky
DFI | Director of Finance/CFO | 68 | 18-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 16-10-31 |
Graham Cooper
CHM | Chairman | 54 | 17-09-30 |
Michael Kauffman
BRD | Director/Board Member | 60 | 16-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 0.7657 | -0.30% | 266,034 |
24-05-16 | 0.768 | -0.56% | 623,270 |
24-05-15 | 0.7723 | -2.18% | 425,070 |
24-05-14 | 0.7895 | +5.62% | 1,219,718 |
24-05-13 | 0.7475 | -3.26% | 1,525,124 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.18% | 55.74M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- KZR Stock